Post-transplantation maintenance with sorafenib or midostaurin for FLT3 positive AML patients–a multicenter retrospective observational study

Shai Shimony*, Moshe Yeshurun, Ofir Wolach, Ron Ram, Uri Rozovski, Liat Shargian, Tsila Zukerman, Odelia Amit, Yael Bar-On, Baher Krayem, Batya Avni, Galit Peretz, Pia Raanani, Oren Pasvolsky

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

The role of post allogeneic stem-cell transplantation (AlloSCT) FLT3 inhibition for acute myeloid leukemia in the real-world setting is unclear, especially in the era of widespread pre-transplant use of tyrosine kinase inhibitors (TKIs). In a multicenter nationwide study, we assessed 41 patients who were treated with post-transplant TKIs (sorafenib, n = 23, midostaurin, n = 18). The majority also received TKIs pre-transplant (n = 32, 79%). After a median follow up of 10 months post-transplant (range 3–53.6), 29 patients (71%) were alive and in complete remission. Similar results were seen in a subgroup analysis of pre-transplant TKI recipients (78%). In Univariate analysis, HCT-CI score < 4 and Type of TKI (sorafenib versus midostaurin) predicted longer overall survival. Seventeen patients (41%) suffered from side effects and seven patients (17%) stopped TKI therapy due to adverse events. Overall, our data suggest that post-transplant use of TKIs is safe and effective in an era of their widespread use prior to AlloSCT.

Original languageEnglish
Pages (from-to)2475-2481
Number of pages7
JournalLeukemia and Lymphoma
Volume62
Issue number10
DOIs
StatePublished - 2021

Keywords

  • Acute myeloid leukemia
  • FLT3 inhibitors
  • post-transplantation maintenance

Fingerprint

Dive into the research topics of 'Post-transplantation maintenance with sorafenib or midostaurin for FLT3 positive AML patients–a multicenter retrospective observational study'. Together they form a unique fingerprint.

Cite this